Tags

Type your tag names separated by a space and hit enter

Semen Parameters Among Transgender Women With a History of Hormonal Treatment.
Urology 2019; 124:136-141U

Abstract

OBJECTIVE

To report on the semen quality parameters in transgender women who pursued semen cryopreservation either in the presence or absence of gender-affirming hormonal medication.

MATERIALS AND METHODS

This retrospective cohort study was conducted as a chart review of consecutive transgender women presenting for semen cryopreservation between January 1, 2012 and March 31, 2018. Demographic data and semen parameters were assessed. Primary outcomes were the semen parameters in subjects with either no exposure, previous exposure or current exposure to gender-affirming hormonal medication.

RESULTS

Twenty-eight patients presented for semen cryopreservation and produced 69 specimens. Using a Kruskal-Wallis test, semen analyses were compared between patients who had never used gender-affirming hormonal medication, those who had previously used hormonal medication but discontinued prior to specimen collection, and those who used medication at the time of specimen collection. Median semen parameters for each group were as follows: volume-2.7 mL, 2.1 mL, 0.9 mL, respectively (P = .12); concentration-63.6 M/mL, 39.0 M/mL, 2.4 M/mL, respectively (P < .01); percent motility-51.5%, 34.3%, 15.6%, respectively (P < .01); and the total motile count was 63.2 M,39.1 M, 0.2 M, respectively (P < .01). Fifteen specimens were collected after discontinuing hormonal medication with a mean discontinuation period of 4.4 months.

CONCLUSION

Specimens collected in the presence of hormonal medication were associated with abnormal semen parameters. Specimens collected after discontinuation of gender-affirming treatments were comparable to transgender women who had never used hormonal medication. Transgender women should be counseled about the potential impact of gender-affirming hormones and to consider fertility preservation prior to gender-affirming treatments.

Authors+Show Affiliations

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA. Electronic address: Amanda.Adeleye@ucsf.edu.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA; Department of Urology, University of California San Francisco, San Francisco, CA.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

30312673

Citation

Adeleye, Amanda J., et al. "Semen Parameters Among Transgender Women With a History of Hormonal Treatment." Urology, vol. 124, 2019, pp. 136-141.
Adeleye AJ, Reid G, Kao CN, et al. Semen Parameters Among Transgender Women With a History of Hormonal Treatment. Urology. 2019;124:136-141.
Adeleye, A. J., Reid, G., Kao, C. N., Mok-Lin, E., & Smith, J. F. (2019). Semen Parameters Among Transgender Women With a History of Hormonal Treatment. Urology, 124, pp. 136-141. doi:10.1016/j.urology.2018.10.005.
Adeleye AJ, et al. Semen Parameters Among Transgender Women With a History of Hormonal Treatment. Urology. 2019;124:136-141. PubMed PMID: 30312673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Semen Parameters Among Transgender Women With a History of Hormonal Treatment. AU - Adeleye,Amanda J, AU - Reid,Garrett, AU - Kao,Chia-Ning, AU - Mok-Lin,Evelyn, AU - Smith,James F, Y1 - 2018/10/10/ PY - 2018/07/27/received PY - 2018/09/09/revised PY - 2018/10/02/accepted PY - 2018/10/13/pubmed PY - 2019/5/15/medline PY - 2018/10/13/entrez SP - 136 EP - 141 JF - Urology JO - Urology VL - 124 N2 - OBJECTIVE: To report on the semen quality parameters in transgender women who pursued semen cryopreservation either in the presence or absence of gender-affirming hormonal medication. MATERIALS AND METHODS: This retrospective cohort study was conducted as a chart review of consecutive transgender women presenting for semen cryopreservation between January 1, 2012 and March 31, 2018. Demographic data and semen parameters were assessed. Primary outcomes were the semen parameters in subjects with either no exposure, previous exposure or current exposure to gender-affirming hormonal medication. RESULTS: Twenty-eight patients presented for semen cryopreservation and produced 69 specimens. Using a Kruskal-Wallis test, semen analyses were compared between patients who had never used gender-affirming hormonal medication, those who had previously used hormonal medication but discontinued prior to specimen collection, and those who used medication at the time of specimen collection. Median semen parameters for each group were as follows: volume-2.7 mL, 2.1 mL, 0.9 mL, respectively (P = .12); concentration-63.6 M/mL, 39.0 M/mL, 2.4 M/mL, respectively (P < .01); percent motility-51.5%, 34.3%, 15.6%, respectively (P < .01); and the total motile count was 63.2 M,39.1 M, 0.2 M, respectively (P < .01). Fifteen specimens were collected after discontinuing hormonal medication with a mean discontinuation period of 4.4 months. CONCLUSION: Specimens collected in the presence of hormonal medication were associated with abnormal semen parameters. Specimens collected after discontinuation of gender-affirming treatments were comparable to transgender women who had never used hormonal medication. Transgender women should be counseled about the potential impact of gender-affirming hormones and to consider fertility preservation prior to gender-affirming treatments. SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/30312673/Semen_Parameters_Among_Transgender_Women_With_a_History_of_Hormonal_Treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(18)31087-2 DB - PRIME DP - Unbound Medicine ER -